Lentigo maligna and superficial spreading melanoma are different in their in situ phase: an immunohistochemical study.
Clinical and pathologic observations have prompted the categorization of malignant melanoma into 4 subtypes. Although some authorities challenge the value of this classification, nevertheless it is generally accepted that lentigo maligna (LM), or melanoma on sun-damaged skin, has a different biological behavior than so-called superficial spreading melanoma (SSM), at least in the early stage of its evolution. To characterize some aspects of this different behavior, the in situ phase of SSM and LM was studied using immunohistochemical methods. Seventeen cases of SSM in situ and 13 cases of LM were chosen for the study. All cases qualified with strict histologic criteria. Sections from these lesions were stained with antibodies against HMB-45 antigen, basic fibroblast growth factor (bFGF), proliferating cell nuclear antigen (PCNA), and factor VIII. Semiquantitative analysis was performed. Cases classified as either LM or SSM corresponded well to the epidemiologic and clinical characteristics as described in the literature; that is, LM appeared in older patients and occurred mostly on the face, whereas SSM occurred mostly on the trunk and lower limbs. Although no difference in HMB-45 stain was observed, melanoctyes of SSM showed greater proliferative activity, as reflected by PCNA stain (P < 0.02) and higher levels of bFGF (P < 0.001), than melanocytes of LM. More blood vessels were counted under SSM than under LM (P < 0.05). These results are in accordance with the biological behavior of SSM and LM, that is, the longer in situ phase of the latter. bFGF is both a growth factor for melanocytes and an angiogentic factor. The differences in PCNA, a proliferation marker, and blood vessel count may be related to the bFGF effect. Thus this study reveals some of the biological differences between LM and SSM. Location and sun exposure habits may contribute to these differences, which already exist in the in situ phase.
Auslender
Silviu
S
Department of Dermatology and Institute of Pathology, Sheba Medical Center, Tel-Hashomer, Israel.
Barzilai
Aviv
A
Goldberg
Iris
I
Kopolovic
Juri
J
Trau
Henri
H
D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000032:analysis*; D005169:Factor VIII / Q000032:analysis; D016222:Fibroblast Growth Factor 2 / Q000032:analysis; D006801:Humans; D018327:Hutchinson's Melanotic Freckle / Q000145:classification / Q000378:metabolism* / Q000473:pathology; D008545:Melanoma / Q000145:classification / Q000378:metabolism* / Q000473:pathology; D058950:Melanoma-Specific Antigens; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis; D009389:Neovascularization, Pathologic; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D012878:Skin Neoplasms / Q000145:classification / Q000378:metabolism* / Q000473:pathology
D000951:Antigens, Neoplasm; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D018809:Proliferating Cell Nuclear Antigen; D016222:Fibroblast Growth Factor 2; D005169:Factor VIII